The Study of Drug 601 in Patients With Diabetic Macular Edema (DME)
NCT ID: NCT04151407
Last Updated: 2019-11-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
50 participants
INTERVENTIONAL
2019-03-08
2020-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Clinical Study Evaluating the Safety, Tolerability and Initial Efficacy of SKG0106 Intravitreal Injection in Diabetic Macular Edema (DME) Patients
NCT06237777
A Study to Evaluate the Efficacy and Safety of IBI302 inSubjects With Diabetic Macular Edema（DME）
NCT06908876
Japanese Safety Study of VEGF Trap-Eye in DME (Diabetic Macular Edema)
NCT01512966
Diabetic Macular Edema (DME) Treatment With Ranibizumab and Dexamethasone or Ranibizumab Only.
NCT04601675
A Study Intravitreal THN391 in Diabetic Macular Oedema Secondary to Non-Proliferative Diabetic Retinopathy.
NCT06701721
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
601 dose level 1 treatment
Recombinant humanized anti-VEGF monoclonal antibody, drug 601(0.375mg), Vitreous injection, injection once;
Drug 601
Drug is a kind of recombinant anti-VEGF humanized monoclonal antibody injection.
601 dose level 2 treatment
Recombinant humanized anti-VEGF monoclonal antibody, drug 601(0.75mg), Vitreous injection, injection once
Drug 601
Drug is a kind of recombinant anti-VEGF humanized monoclonal antibody injection.
601 dose level 3 treatment
Recombinant humanized anti-VEGF monoclonal antibody, drug 601(1.25mg), Vitreous injection, injection once
Drug 601
Drug is a kind of recombinant anti-VEGF humanized monoclonal antibody injection.
601 dose level 4 treatment
Recombinant humanized anti-VEGF monoclonal antibody, drug 601(2.5mg), Vitreous injection, injection once;
Drug 601
Drug is a kind of recombinant anti-VEGF humanized monoclonal antibody injection.
601 dose level 5 treatment
Recombinant humanized anti-VEGF monoclonal antibody, drug 601(3.75mg), Vitreous injection, injection once;
Drug 601
Drug is a kind of recombinant anti-VEGF humanized monoclonal antibody injection.
601 dose level 6 treatment
Recombinant humanized anti-VEGF monoclonal antibody, drug 601(1.25mg), Vitreous injection, injection once every 4 weeks, three times continuously.
Drug 601
Drug is a kind of recombinant anti-VEGF humanized monoclonal antibody injection.
601 dose level 7 treatment
Recombinant humanized anti-VEGF monoclonal antibody, drug 601(2.5mg), Vitreous injection, injection once every 4 weeks, three times continuously.
Drug 601
Drug is a kind of recombinant anti-VEGF humanized monoclonal antibody injection.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Drug 601
Drug is a kind of recombinant anti-VEGF humanized monoclonal antibody injection.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age \>= 18 years and age =\< 75 years
* Diagnosis of type 1 or type 2 diabetes
* Hemoglobin (HbA1c) value =\< 11%
* The study eye must meet the following criteria
* Diabetic macular edema with central fovea involvement and visual impairment in subjects;
* Best corrected visual acuity letter score (ETDRS)\>= 19 (i.e., 20/400 or better) and \<= 73 (i.e., 20/40 or worse)in the study eye;
* CRT ≥ 275 μm;
* No optometric media opacity and pupil shrinkage.
* Best corrected visual acuity letter score (ETDRS) \> =24 (i.e., 20/320 or better)in the fellow eyes
Exclusion Criteria
* The study eye has proliferative diabetic retinopathy (PDR), except for the PDR with regression after panretinal photocoagulation, and Inactive, fibrotic PDR
* History of vitreous hemorrhage in the study eye within 2 months before screening
* Structural retinal damage with fovea in the study eye (e.g. retinal pigment epithelium(RPE) atrophy, retinal fibrosis, laser scarring, dense hard exudation), or researchers believe that the study eye has other retinal damage that may hinder visual improvement after macular edema subsides
* In addition to diabetic retinopathy, there are other causes of macular edema or visual changes in the study eye.
Ophthalmic conditions (e.g.,retinal vein occlusion (RVO) Choroidal neovascularization, retinal detachment, macular hole, retinal traction in macular region, epiretinal membrane, etc.)
* Iris neovascularization in the study eye;
* Uncontrollable glaucoma in the study eye (defined as intraocular pressure after antiglaucoma medication\>= 25 mm Hg), or glaucoma filtering surgery history;
* Researchers believe that cataract in the study eye may affect the judgement of examination or test results, or surgical treatment is required in 6 months following screening
* The study eye has no lens( except intraocular lens)
* History of Intraocular injection for corticosteroids (e.g. triamcinolone) at any time in the past 3 months, or corticosteroids injection around the eyes within one month before screening
* History of vitrectomy in the studyeye
* History of panretinal photocoagulation in the study eye in the past 6 months before screening; or panretinal photocoagulation may be required following screening
* Study eye have received more than two local/grid retinal photocoagulation treatments, or history of local/grid retinal photocoagulation treatments in the study eye in the past 3 months before screening
* History of anti-VEGF drugs treatments(e.g. Abercept, Pigatani Sodium, Razumab, Bevacizumab, etc.) in any eye or system within 3 months before screening;
* History of any intraocular surgery (e.g. cataract surgery, YAG posterior capsulotomy, etc) in the study eye within 3 months before screening;
* History of ophthalmic surgery involving macular areas (e.g. PDT, macular transposition) in the study eye, except for local/grid retinal photocoagulation
Any of the following general condition are present:
* Uncontrolled blood pressure control (defined as systolic blood pressure \> 150 mmHg or diastolic pressure \> 95 mmHg after antihypertensive medication
* The subjects is suffering from systemic infections and requiring oral, intramuscular or intravenous medication
* History of stroke, transient ischemic attack, myocardial infarction or acute congestive heart failure in the past 6 months before screening;
* Medicines with toxicity to the lens, retina or optic nerve (deferoxamine, chloroquine,hydroxychloroquine (chloroquine), tamoxifen and phenol etc.) is being used or may be used during the study period
* Diagnosed systemic immune diseases (e.g. ankylosing spondylitis and systemic lupus erythematosus etc.), or any uncontrolled clinical problem (e.g. AIDS, malignant tumors, active hepatitis, serious mental, neurological, cardiovascular, respiratory and other systemic diseases, etc.)
* History of allergy to fluorescein sodium and allergies to protein products for treatment or diagnosis, history of allergy to more than two drugs and/or non-drug factors, or suffering from allergic diseases now
Any of the following laboratory tests abnormalities:
* Diabetic patients with uncontrolled blood glucose (fasting blood glucose \>= 8.8 mmol/L);
* Renal function impairment (Cr is 1.5 times higher than the upper limit of normal values in the local laboratory) Liver dysfunction (ALT or AST is 2 times higher than the upper limit of normal value in the local laboratory).
* Abnormal coagulation function (prothrombin time \>= the upper limit of normal value for 3 seconds) and activated partial thromboplastin time \>= the upper limit of normal value for 10 seconds)
Patients with childbearing age with any of the following conditions:
\- Those who do not use effective contraceptive measures;
The following are not excluded:
1. Natural amenorrhea for more than 12 months, or natural amenorrhea for 6 months and the serum follicle-stimulating hormone level \> 40 mIU/mL;
2. Bilateral ovariectomy with/without hysterectomy for more than 6 weeks;
3. Use acceptable contraceptive methods(Sterilization, hormone contraception,Intrauterine device, double barrier method)
4. Be able to use reliable contraceptives throughout the study period and stick to the end of the visit, (Unacceptable contraceptive methods include regular abstinence by calendar, ovulation, body temperature measurement, post-ovulation and fertilization in vitro);
* Pregnancy and lactation women (pregnancy is defined as urinary pregnancy test positive in this study)
* Participation in any other drug clinical trials (except vitamins and minerals) in the past 1 month before screening
* Researchers think it needs to be ruled out.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chinese PLA General Hospital of Central Theater.
Wuhan, Hubei, China
JiangSu Province Hospital
Nanjing, Jiangsu, China
Shanghai General Hospital
Shanghai, Shanghai Municipality, China
West China Hospital of Sichuan University
Chengdu, Sichuan, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
YanPing Song, PhD
Role: primary
Huai Qing Liu, PhD
Role: primary
Xiaodong Sun, PHD
Role: primary
Ming Zhang, PhD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SSGJ-601-DME-I-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.